Teos Therapeutics downgraded to Hold after belrestotug failure and GSK deal ending. Read my updated analysis on ITOS stock ...

This follows what appeared to be a generally positive data readout for belrestotug at ESMO 2024 just a few months ago.

Fintel reports that on May 14, 2025, Leerink Partners downgraded their outlook for iTeos Therapeutics (NasdaqGM:ITOS) from ...

Belrestotug showed underwhelming efficacy outcomes in mid-stage studies of non-small cell lung cancer and head and neck ...

Decision follows underwhelming Phase II results from GALAXIES Lung-201 and H&N-202 trials, prompting iTeos and GSK to end ...

GSK plc with its development partner iTeos Therapeutics, Inc., has announced that it is ending the development programme for ...

GSK has agreed to pay $1.2 billion upfront to acquire rights to efimosfermin from Cambridge, Massachusetts-based Boston ...

GSK has already moved on from its decision to drop a cancer asset on Tuesday by snagging a late-stage liver disease candidate ...

TerraVest Industries Inc (TVK.T) is expected to report for 2Q. United Homes Group Inc (UHG) is expected to report for 1Q. Valeura Energy Inc (PNWRF,VLE.T) is expected to report for 1Q. Vislink ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, ...

Join Plus500 today and get up to $200 to start trading real futures. Practice with free paper trading, then jump into live ...